TherapeuticsMD

TherapeuticsMD, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm's technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. It also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(567) thousand, or $(0.05) per basic and diluted common share, compared to a net loss of $(1.4) million, or $(0.13) per basic and d.

TherapeuticsMD Announces Third Quarter 2024 Financial Results

The Dow Jones index closed higher by more than 450 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.

TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(1.05) million, or $(0.09) per basic and diluted common share, compared to a net loss of $(2.4) million, or $(0.24) per basic and dilu.

TherapeuticsMD Announces Second Quarter 2024 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(0.8) million, or $(0.07) per basic and diluted common share, compared to net loss from continuing operations of $(2.3) million, or $(0.

TherapeuticsMD Announces First Quarter 2024 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023. “We continue to explore a variety of strategic alternatives with the goal of maximizing value for our shareholders,” stated Marlan D. Walker, Chief Executive Officer of TherapeuticsMD. Full Year 2023 Financial Results Net Income (Loss) from Continuing Operati.

TherapeuticsMD Announces Full Year 2023 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2023. “As the Company continues its transition into a royalty-based business, we remain committed to cost control to maximize the value of our royalty assets,” stated Marlan D. Walker, Chief Executive Officer of TherapeuticsMD. Third Quarter 2023 Financial Res.

TherapeuticsMD Announces Third Quarter 2023 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2023. “The Company's transformation into a royalty-based business is ongoing. As we phase out our historical business operations, we remain focused on reducing costs and conserving cash,” stated Marlan D. Walker, Chief Executive Officer of TherapeuticsMD. Second Q.

TherapeuticsMD Announces Second Quarter 2023 Financial Results

TXMD is a pharmaceutical company that experienced a tremendous transformation in the last year, fully transforming into a royalty-only company. The company sold all its assets and paid down all its debt and is now expecting 8% of royalties plus $30 million in milestone payments from Mayne Pharma.

TherapeuticsMD: From Fallen And Forgotten To Cash Cow

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $2.3 million for the quarter ended March 31, 2023, or $0.24 per basic and diluted common share, compared to a net loss from continuing operations.

TherapeuticsMD Announces First Quarter 2023 Financial Results

TherapeuticsMD (TXMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to Buy

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2022.

TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition

BOCA RATON, Fla.--( BUSINESS WIRE )--TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women's healthcare company, today announced that it has completed its previously announced transaction with Mayne Pharma Group Limited (“Mayne Pharma”), an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, pursuant to which TXMD granted Mayne Pharma an exclusive license to commercialize TXMD's products in the United States. In addition, TXMD sold certain assets to Mayne Pharma to enable it to commercialize the products.

TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma

BOCA RATON, Fla.--( BUSINESS WIRE )--TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women's healthcare company, today announced that it has entered into definitive agreements to license its products to an affiliate of Mayne Pharma Group Limited (“Mayne Pharma”), an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, for commercialization in the United States. In addition, TXMD has agreed to sell certain assets to Mayne Pharma to allow Mayne Pharma to commercialize the products.

TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -53.43% and 30.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates

BOCA RATON, Fla.--( BUSINESS WIRE )--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today reported financial results for the third quarter ended September 30, 2022.

TherapeuticsMD Announces Third Quarter 2022 Financial Results

TherapeuticsMD Announces Additional $7 Million Private Placement

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women's healthcare company, announced today that it received a $7 million private investment in the Company's Series A Preferred Stock from Rubric Capital Management LP (“Rubric”). TherapeuticsMD expects to use the proceeds from the transaction for working capital. Under the terms of the Company's financing agreement with its lender, Sixth Street Specialty Lending,

TherapeuticsMD Announces $7 Million Private Placement

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women's healthcare company, announced today the appointment of Dr. Brian Bernick and Mr. Mark Glickman as the Company's Interim Co-Chief Executive Officers and Co-Principal Executive Officers. Dr. Bernick and Mr. Glickman succeed Mr. Hugh O'Dowd as the Company's Chief Executive Officer. Prior to this appointment, Dr. Bernick, the Company's co-founder, served as Chie

TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 29.28% and 23.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates

TherapeuticsMD, Inc. (NASDAQ:TXMD ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 PM ET Company Participants Lisa Wilson - IR Hugh O'Dowd - CEO Michael Donegan - Interim CFO Mark Glickman - Chief Commercial Officer Conference Call Participants Douglas Tsao - H.C. Wainwright Operator [Starts Abruptly] for the Therapeutics MD's Second Quarter 2022 Financial Results Conference Call.

TherapeuticsMD, Inc. (TXMD) CEO Hugh O'Dowd on Q2 2022 Results - Earnings Call Transcript

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today reported financial results for the Second Quarter ended June 30, 2022. “We saw solid revenue growth during the quarter, with an increase of 24% over the prior year period, while also experiencing a 21% decrease in operating expenses. The U.S. Food and Drug Administration's recent approval of our supplemental new drug application for ANNOVERA

TherapeuticsMD Announces Second Quarter 2022 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced that it will report its second quarter 2022 financial results on Monday, August 15, 2022, at 8:30 a.m. ET prior the opening of the U.S. financial markets. Executive management will host a conference call and webcast to discuss the results and provide a business update as follows: Date:   Monday, August 15, 2022 Time:   8:30 a.m. ET

TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women's healthcare company, announced today that it has received a $15 million private investment in the Company's common stock and a new series of preferred stock (“PIPE”) from Rubric Capital Management LP (“Rubric”). TherapeuticsMD expects to use the proceeds from the transaction to fulfill its near-term operating capital requirements. The Company also entered int

TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital

Women's healthcare company TherapeuticsMD Inc (NASDAQ: TXMD) shares are falling as EW Healthcare Partners did not acquire the required majority of shares of TXMD through the previously announced tender offer by the extended deadline. TherapeuticsMD's products are.

Why TherapeuticsMD Shares Are Sinking Today?

Shares of TherapeuticsMD Inc. TXMD, +8.67% tumbled 41.6% in premarket trading on Wednesday after the women's health company told investors that EW Healthcare Partners' planned acquisition of TherapeuticsMD isn't expected to go through. The tender offer expired Tuesday.

News for TherapeuticsMD Stock (TXMD)